Sector News

Alexion Pharma Appoints Leonard Bell As Chairman

October 13, 2014
Life sciences
(RTTNews) – Alexion Pharmaceuticals Inc. announced that it has appointed Leonard Bell as Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company.
 
In addition, Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999. Norby currently serves as Chair of the Audit Committee, a member of the Nominating and Corporate Governance Committee, and a member of the Risk and Strategy Committee.
 
Both of these appointments follow the passing of Max Link, Ph.D., as announced earlier this week, who served as the Chairman of the Board of Directors of Alexion since December 2002 and as a member of the Board since the Company’s inception in 1992.

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach